Cargando…

Age Differences in Cardiopulmonary Exercise Testing Parameters in Heart Failure with Reduced Ejection Fraction

Background and Objectives: Cardiopulmonary exercise testing (CPET) is a cornerstone of risk stratification in heart failure with reduced ejection fraction (HFrEF). However, there is a paucity of evidence on its predictive power in older patients. The aim of this study was to evaluate the prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia Brás, Pedro, Gonçalves, António Valentim, Reis, João Ferreira, Moreira, Rita Ilhão, Pereira-da-Silva, Tiago, Rio, Pedro, Timóteo, Ana Teresa, Silva, Sofia, Soares, Rui M., Ferreira, Rui Cruz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535443/ https://www.ncbi.nlm.nih.gov/pubmed/37763804 http://dx.doi.org/10.3390/medicina59091685

Ejemplares similares

Cardiopulmonary Exercise Testing in the Age of New Heart Failure Therapies: Still a Powerful Tool?
por: Garcia Brás, Pedro, et al.
Publicado: (2023)

Cardiopulmonary Exercise Testing in Patients with Heart Failure: Impact of Gender in Predictive Value for Heart Transplantation Listing
por: Garcia Brás, Pedro, et al.
Publicado: (2023)

Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
por: Reis, João, et al.
Publicado: (2022)

Sacubitril/Valsartan Improves Left Atrial and Ventricular Strain and Strain Rate in Patients with Heart Failure with Reduced Ejection Fraction
por: Brás, Pedro Garcia, et al.
Publicado: (2023)

Prognostic Prediction of Cardiopulmonary Exercise Test Parameters in Heart Failure Patients with Atrial Fibrillation
por: Gonçalves, António Valentim, et al.
Publicado: (2020)

Capacidade Preditiva dos Parâmetros do Teste de Esforço Cardiopulmonar em Pacientes com Insuficiência Cardíaca em Terapia de Ressincronização Cardíaca
por: Reis, João Ferreira, et al.
Publicado: (2022)

O Impacto da Aptidão Cardiorrespiratória no Paradoxo da Obesidade em Insuficiência Cardíaca com Fração de Ejeção Reduzida
por: Moreira, Rita Ilhão, et al.
Publicado: (2020)

Tratamento Ambulatorial de Levosimedana por 6 Horas como Ponte para Transplante Cardíaco
por: Gonçalves, António Valentim, et al.
Publicado: (2023)

Melhora no Consumo Máximo de Oxigênio e na Ventilação após Tratamento com Sacubitril-Valsartana
por: Gonçalves, António Valentim, et al.
Publicado: (2020)

Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
por: Valentim Gonçalves, António, et al.
Publicado: (2019)

Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update
por: Vaz-Salvador, Pedro, et al.
Publicado: (2022)

A Large Cardiac Metastasis of a Parathyroid Tumour Presenting with Ventricular Tachycardia
por: Moreira, Rita Ilhão, et al.
Publicado: (2019)

Outcomes in Pregnant Women with Valvular Heart Disease from Portuguese-Speaking African Countries Treated in Portugal through an International Agreement of Health Cooperation
por: Ferreira, Vera Vaz, et al.
Publicado: (2023)

Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
por: Neves, João Sérgio, et al.
Publicado: (2022)

Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial
por: Ferreira, João Pedro, et al.
Publicado: (2019)

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction
por: Giallauria, Francesco, et al.
Publicado: (2020)

Non‐invasive telemonitoring improves outcomes in heart failure with reduced ejection fraction: a study in high‐risk patients
por: Nunes‐Ferreira, Afonso, et al.
Publicado: (2020)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Prognostic impact of bundle branch block after acute coronary syndrome. Does it matter if it is left of right?
por: Timóteo, Ana Teresa, et al.
Publicado: (2018)

An Alternative Method to Calculate Simplified Projected Aortic Valve Area at Normal Flow Rate
por: Ferreira, Joana Sofia Silva Moura, et al.
Publicado: (2018)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Myocardial Work Brings New Insights into Left Ventricular Remodelling in Cardio-Oncology Patients
por: Vaz Ferreira, Vera, et al.
Publicado: (2022)

Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction
por: Nadruz, Wilson, et al.
Publicado: (2017)

The effect of different anaesthetics on echocardiographic evaluation of diastolic dysfunction in a heart failure with preserved ejection fraction model
por: Cuijpers, Ilona, et al.
Publicado: (2020)

The role of miRNAs in the diagnosis of stable atherosclerosis of different arterial territories: A critical review
por: Teixeira, Ana Rita, et al.
Publicado: (2022)

Heart Failure with Reduced Ejection Fraction and Prognostic Scales: The Impact of Exercise Modality in Cardiopulmonary Exercise Tests
por: Herrero Huertas, Julia, et al.
Publicado: (2022)

Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy
por: Nottebohm, Pia I., et al.
Publicado: (2022)

Effect of Nebivolol on MIBG Parameters and Exercise in Heart Failure with Normal Ejection Fraction
por: Messias, Leandro Rocha, et al.
Publicado: (2016)

Associations of medicine use and ejection fraction with the coexistence of frailty and sarcopenia in a sample of heart failure outpatients: a cross-sectional study
por: Valdiviesso, Rui, et al.
Publicado: (2023)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation
por: Silva Cunha, Pedro, et al.
Publicado: (2022)

Microvascular Dysfunction Is Associated With Impaired Myocardial Work in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Multimodality Study
por: Garcia Brás, Pedro, et al.
Publicado: (2023)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial
por: Pocock, Stuart J., et al.
Publicado: (2022)

The Effect of Cardiac Rehabilitation Exercise Training on Cardiopulmonary Function in Ischemic Cardiomyopathy With Reduced Left Ventricular Ejection Fraction
por: Kim, Chul, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dp595oq1oe6j6q8ntpjvqhji26